β-Cell failure in type 2 diabetes

Postulated mechanisms and prospects for prevention and treatment

Philippe A. Halban, Kenneth S. Polonsky, Donald W. Bowden, Meredith A. Hawkins, Charlotte Ling, Kieren J. Mather, Alvin C. Powers, Christopher J. Rhodes, Lori Sussel, Gordon C. Weir

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

OBJECTIVE This article examines the foundation of β-Cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlyingmechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-Cell failure, natural history of β-Cell failure, and impact of therapeutic interventions. CONCLUSIONS β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-Cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-Cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-Cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.

Original languageEnglish (US)
Pages (from-to)1751-1758
Number of pages8
JournalDiabetes Care
Volume37
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Type 2 Diabetes Mellitus
Therapeutics
Natural History
Genetic Loci
Genetic Predisposition to Disease
Cell- and Tissue-Based Therapy
Metabolic Networks and Pathways
Research Design
Brain

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing
  • Medicine(all)

Cite this

Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., ... Weir, G. C. (2014). β-Cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. Diabetes Care, 37(6), 1751-1758. https://doi.org/10.2337/dc14-0396

β-Cell failure in type 2 diabetes : Postulated mechanisms and prospects for prevention and treatment. / Halban, Philippe A.; Polonsky, Kenneth S.; Bowden, Donald W.; Hawkins, Meredith A.; Ling, Charlotte; Mather, Kieren J.; Powers, Alvin C.; Rhodes, Christopher J.; Sussel, Lori; Weir, Gordon C.

In: Diabetes Care, Vol. 37, No. 6, 2014, p. 1751-1758.

Research output: Contribution to journalArticle

Halban, PA, Polonsky, KS, Bowden, DW, Hawkins, MA, Ling, C, Mather, KJ, Powers, AC, Rhodes, CJ, Sussel, L & Weir, GC 2014, 'β-Cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment', Diabetes Care, vol. 37, no. 6, pp. 1751-1758. https://doi.org/10.2337/dc14-0396
Halban, Philippe A. ; Polonsky, Kenneth S. ; Bowden, Donald W. ; Hawkins, Meredith A. ; Ling, Charlotte ; Mather, Kieren J. ; Powers, Alvin C. ; Rhodes, Christopher J. ; Sussel, Lori ; Weir, Gordon C. / β-Cell failure in type 2 diabetes : Postulated mechanisms and prospects for prevention and treatment. In: Diabetes Care. 2014 ; Vol. 37, No. 6. pp. 1751-1758.
@article{2228b3cd54e342a488d1a25c4c905f20,
title = "β-Cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment",
abstract = "OBJECTIVE This article examines the foundation of β-Cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlyingmechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-Cell failure, natural history of β-Cell failure, and impact of therapeutic interventions. CONCLUSIONS β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-Cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-Cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-Cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.",
author = "Halban, {Philippe A.} and Polonsky, {Kenneth S.} and Bowden, {Donald W.} and Hawkins, {Meredith A.} and Charlotte Ling and Mather, {Kieren J.} and Powers, {Alvin C.} and Rhodes, {Christopher J.} and Lori Sussel and Weir, {Gordon C.}",
year = "2014",
doi = "10.2337/dc14-0396",
language = "English (US)",
volume = "37",
pages = "1751--1758",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - β-Cell failure in type 2 diabetes

T2 - Postulated mechanisms and prospects for prevention and treatment

AU - Halban, Philippe A.

AU - Polonsky, Kenneth S.

AU - Bowden, Donald W.

AU - Hawkins, Meredith A.

AU - Ling, Charlotte

AU - Mather, Kieren J.

AU - Powers, Alvin C.

AU - Rhodes, Christopher J.

AU - Sussel, Lori

AU - Weir, Gordon C.

PY - 2014

Y1 - 2014

N2 - OBJECTIVE This article examines the foundation of β-Cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlyingmechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-Cell failure, natural history of β-Cell failure, and impact of therapeutic interventions. CONCLUSIONS β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-Cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-Cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-Cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.

AB - OBJECTIVE This article examines the foundation of β-Cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlyingmechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-Cell failure, natural history of β-Cell failure, and impact of therapeutic interventions. CONCLUSIONS β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-Cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-Cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-Cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.

UR - http://www.scopus.com/inward/record.url?scp=84901445280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901445280&partnerID=8YFLogxK

U2 - 10.2337/dc14-0396

DO - 10.2337/dc14-0396

M3 - Article

VL - 37

SP - 1751

EP - 1758

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -